Symbol="AKBA"
AssetType="Common Stock"
Name="Akebia Ther"
Description="Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts."
CIK="1517022"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="245 FIRST STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="232410000"
EBITDA="33399000"
PERatio="None"
PEGRatio="0"
BookValue="-0.077"
DividendPerShare="0"
DividendYield="0"
EPS="-0.31"
RevenuePerShareTTM="1.472"
ProfitMargin="-0.208"
OperatingMarginTTM="-0.0158"
ReturnOnAssetsTTM="-0.0066"
ReturnOnEquityTTM="-9.58"
RevenueTTM="271030000"
GrossProfitTTM="141801000"
DilutedEPSTTM="-0.31"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.35"
AnalystTargetPrice="3"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="0.281"
PriceToBookRatio="4.117"
EVToRevenue="0.0443"
EVToEBITDA="-0.13"
Beta="0.77"
num_52WeekHigh="1.84"
num_52WeekLow="0.241"
num_50DayMovingAverage="1.242"
num_200DayMovingAverage="0.848"
SharesOutstanding="185928000"
DividendDate="None"
ExDividendDate="None"
symbol="AKBA"
open="1.23"
high="1.32"
low="1.12"
price="1.15"
volume="2612998.00"
latest_trading_day="2023-08-25"
previous_close="1.25"
change="-0.10"
change_percent="-8.0000%"
aroon_positive_momentum_days="74"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="74"
Volume_recent_avg="1824004"
Change_recent_avg="0.01"
Delta_recent_avg="0.12"
Variance_recent_avg="0.06"
Change_ratio_recent_avg="0.06"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="74"
Aroon_momentum_negative="26"
image_negative_thumbnail_id_1="508"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0097.jpeg"
image_negative_thumbnail_id_2="114"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0062.jpeg"
image_neutral_thumbnail_id_1="538"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0061.jpeg"
image_neutral_thumbnail_id_2="574"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0025.jpeg"
image_positive_thumbnail_id_1="609"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0099.jpeg"
image_positive_thumbnail_id_2="707"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0001.jpeg"
image_professor_thumbnail_id_1="1175"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
image_professor_thumbnail_id_2="1190"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0024.jpeg"
